BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33503056)

  • 1. Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options.
    Bosquet JG; Zhang Q; Cliby WA; Bakkum-Gamez JN; Cen L; Dowdy SC; Sherman ME; Weroha SJ; Clayton AC; Kipp BR; Halling KC; Couch FJ; Podratz KC
    PLoS One; 2021; 16(1):e0245664. PubMed ID: 33503056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
    Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
    PLoS One; 2022; 17(12):e0278408. PubMed ID: 36454788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
    Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
    Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile.
    Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
    Front Oncol; 2023; 13():1105504. PubMed ID: 37287928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data.
    Huo X; Sun H; Cao D; Yang J; Peng P; Yu M; Shen K
    Sci Rep; 2019 Jul; 9(1):9924. PubMed ID: 31289358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
    Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
    PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
    Koul A; Bendahl PO; Borg A; Fernö M; Lidebring MF; Högberg T; Einarsson EL; Ridderheim M; Willén R
    Int J Gynecol Cancer; 2002; 12(4):362-71. PubMed ID: 12144684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
    Urick ME; Bell DW
    Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiomics profiling of the expression and prognosis of MCMs in endometrial carcinoma.
    Lan H; Yuan J; Chen X; Liu C; Guo X; Wang X; Song J; Cao K; Xiao S
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34859821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer.
    Jiang F; Jiang S; Cao D; Mao M; Xiang Y
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and genes associated with endometrial cancer based on gene expression profiling by bioinformatics analysis.
    Zhang Y; Zhang W; Li X; Li D; Zhang X; Yin Y; Deng X; Sheng X
    Arch Gynecol Obstet; 2016 Jun; 293(6):1287-95. PubMed ID: 26437953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel miRNA markers for the diagnosis and prognosis of endometrial cancer.
    Wang Q; Xu K; Tong Y; Dai X; Xu T; He D; Ying J
    J Cell Mol Med; 2020 Apr; 24(8):4533-4546. PubMed ID: 32150330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCAPH is upregulated in endometrial cancer and associated with poor clinicopathologic characteristics.
    Qiu X; Gao Z; Shao J; Li H
    Ann Hum Genet; 2020 Nov; 84(6):437-446. PubMed ID: 32628282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer.
    Wang Y; Zhao S; Qin Q; Gao X; Zhang X; Zhang M; Jiang Y; Ji X; Zhu H; Zhao X; Li H
    PLoS One; 2022; 17(1):e0262000. PubMed ID: 35077462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.